A large body of evidence indicates that the presence of regulatory T cells (Tregs) in tumors is
associated with a dampened tumor-specific immune response and a clear negative impact
on survival. Many different subsets of Tregs have been identified, which all act through
similar or distinct pathways to suppress tumor-specific effector cells. The observation that
tumor-infiltrating Tregs are able to recognize tumor-derived antigens and can be expanded
by vaccines that primarily aim at reinforcing the effector arm of the antitumor response …